Oklahoma City, OK
4 risk indicators measuring financial stability and operational resilience
Sign in with your work email to view Tuckman-Chang indicators
Sign In — Free (10 views/day)Oklahoma Medical Research Foundation, founded in 1946, is a major nonprofit in the Medical Research sector that reported $114.3M in total revenue in fiscal year 2022. Expenses of $108.1M left a modest 5% surplus.
Oklahoma Medical Research Foundation (OMRF) is dedicated to developing a better understanding of and more effective treatments for human disease.
Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency
Sign in to view Trantor Score and financial metrics
Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)
Sign In — Free (10 views/day)| 2022 | 2021 | Change | |
|---|---|---|---|
| Revenue | $114,311,660 | $107,744,875 | +0.1% |
| Expenses | $108,085,497 | $96,940,173 | +0.1% |
| Net Income | $6,226,163 | $10,804,702 | -0.4% |
Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics
Financial Distress Indicator
Liquidity & Cash Position
Sign in to view all financial metrics
Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics
Sign In| Name | Title | Hours/Week | Role | Reportable Comp | Other Comp | Total |
|---|---|---|---|---|---|---|
| N/A | Board Member | 1.0 |
Director
|
$0 | $0 | $0 |
| N/A | Board Member | 1.0 |
Director
|
$0 | $0 | $0 |
| N/A | Board Member | 1.0 |
Director
|
$0 | $0 | $0 |
| N/A | Board Member | 1.0 |
Director
|
$0 | $0 | $0 |
| N/A | Board Member | 1.0 |
Director
|
$0 | $0 | $0 |
| N/A | Board Member | 1.0 |
Director
|
$0 | $0 | $0 |
| N/A | Board Member | 1.0 |
Director
|
$0 | $0 | $0 |
| N/A | Board Member | 1.0 |
Director
|
$0 | $0 | $0 |
| N/A | Board Member | 1.0 |
Director
|
$0 | $0 | $0 |
| N/A | Board Member | 1.0 |
Director
|
$0 | $0 | $0 |
| N/A | Board Member | 1.0 |
Director
|
$0 | $0 | $0 |
| N/A | Board Member | 1.0 |
Director
|
$0 | $0 | $0 |
| N/A | Board Member | 1.0 |
Director
|
$0 | $0 | $0 |
| N/A | Board Member | 1.0 |
Director
|
$0 | $0 | $0 |
| N/A | Board Member | 1.0 |
Director
|
$0 | $0 | $0 |
| N/A | Board Member | 1.0 |
Director
|
$0 | $0 | $0 |
| N/A | Board Member | 1.0 |
Director
|
$0 | $0 | $0 |
| N/A | Board Member | 1.0 |
Director
|
$0 | $0 | $0 |
| N/A | Board Member | 1.0 |
Director
|
$0 | $0 | $0 |
| N/A | Board Member | 1.0 |
Director
|
$0 | $0 | $0 |
| N/A | Board Member | 1.0 |
Director
|
$0 | $0 | $0 |
| N/A | Board Member | 1.0 |
Director
|
$0 | $0 | $0 |
| N/A | Board Member | 1.0 |
Director
|
$0 | $0 | $0 |
| N/A | Board Member | 1.0 |
Director
|
$0 | $0 | $0 |
| N/A | Board Member | 1.0 |
Director
|
$0 | $0 | $0 |
| N/A | Board Member | 1.0 |
Director
|
$0 | $0 | $0 |
| N/A | Board Member | 1.0 |
Director
|
$0 | $0 | $0 |
| N/A | Board Member | 1.0 |
Director
|
$0 | $0 | $0 |
| N/A | Board Member | 1.0 |
Director
|
$0 | $0 | $0 |
| N/A | Board Member | 1.0 |
Director
|
$0 | $0 | $0 |
| N/A | Board Member | 1.0 |
Director
|
$0 | $0 | $0 |
| N/A | Board Member | 1.0 |
Director
|
$0 | $0 | $0 |
| N/A | Board Member | 1.0 |
Director
|
$0 | $0 | $0 |
| N/A | Board Member | 1.0 |
Director
|
$0 | $0 | $0 |
| N/A | Board Member | 1.0 |
Director
|
$0 | $0 | $0 |
| N/A | Board Member | 1.0 |
Director
|
$0 | $0 | $0 |
| N/A | Board Member | 1.0 |
Director
|
$0 | $0 | $0 |
| N/A | Board Member | 1.0 |
Director
|
$0 | $0 | $0 |
| N/A | Board Member | 1.0 |
Director
|
$0 | $0 | $0 |
| N/A | Board Member | 1.0 |
Director
|
$0 | $0 | $0 |
| N/A | Board Member | 1.0 |
Director
|
$0 | $0 | $0 |
| N/A | Board Member | 1.0 |
Director
|
$0 | $0 | $0 |
| N/A | Board Member | 1.0 |
Director
|
$0 | $0 | $0 |
| N/A | Board Member | 1.0 |
Director
|
$0 | $0 | $0 |
| N/A | Board Member | 1.0 |
Director
|
$0 | $0 | $0 |
| N/A | Board Member | 1.0 |
Director
|
$0 | $0 | $0 |
| N/A | Board Member | 1.0 |
Director
|
$0 | $0 | $0 |
| N/A | Board Member | 1.0 |
Director
|
$0 | $0 | $0 |
| N/A | Board Member | 1.0 |
Director
|
$0 | $0 | $0 |
| N/A | Board Member | 1.0 |
Director
|
$0 | $0 | $0 |
| N/A | Board Member | 1.0 |
Director
|
$0 | $0 | $0 |
| N/A | Board Member | 1.0 |
Director
|
$0 | $0 | $0 |
| N/A | Board Member | 1.0 |
Director
|
$0 | $0 | $0 |
| N/A | Board Member | 1.0 |
Director
|
$0 | $0 | $0 |
| N/A | Board Member | 1.0 |
Director
|
$0 | $0 | $0 |
| N/A | Board Member | 1.0 |
Director
|
$0 | $0 | $0 |
| N/A | Board Member | 1.0 |
Director
|
$0 | $0 | $0 |
| N/A | Board Member | 1.0 |
Director
|
$0 | $0 | $0 |
| N/A | Board Member | 1.0 |
Director
|
$0 | $0 | $0 |
| N/A | Board Member | 1.0 |
Director
|
$0 | $0 | $0 |
| N/A | Board Member | 1.0 |
Director
|
$0 | $0 | $0 |
| N/A | Board Member | 1.0 |
Director
|
$0 | $0 | $0 |
| N/A | Sr VP and General Counsel | 50.0 |
Officer
|
$340,415 | $57,319 | $397,734 |
| N/A | President and CEO | 50.0 |
Officer
|
$672,712 | $85,296 | $758,008 |
| N/A | VP of Human Resources | 50.0 |
Officer
|
$199,778 | $45,418 | $245,196 |
| N/A | VP of Research (Training) | 50.0 |
Officer
|
$218,793 | $40,159 | $258,952 |
| N/A | VP of Clinical Affairs and Program Chair | 50.0 |
Officer
|
$475,957 | $104,442 | $580,399 |
| N/A | VP of Government Affairs | 50.0 |
Officer
|
$178,756 | $31,619 | $210,375 |
| N/A | VP of Philanthropy | 50.0 |
Officer
|
$246,527 | $63,779 | $310,306 |
| N/A | VP of Research | 50.0 |
Officer
|
$349,220 | $45,732 | $394,952 |
| N/A | VP and CFO | 50.0 |
Officer
|
$282,285 | $66,629 | $348,914 |
| N/A | Program Chair, Aging and Metabolism | 50.0 |
Key Emp
|
$167,302 | $22,605 | $189,907 |
| N/A | Associate Professor, Arthritis and Clinical Immunology | 50.0 |
Key Emp
|
$368,736 | $54,656 | $423,392 |
| N/A | Program Chair, Cardiovascular Biology | 50.0 |
Key Emp
|
$302,230 | $72,758 | $374,988 |
| N/A | Program Chair, Genes and Human Disease | 50.0 |
Key Emp
|
$310,352 | $62,858 | $373,210 |
| N/A | Professor, Cardiovascular Biology | 50.0 |
Highest
|
$250,227 | $41,421 | $291,648 |
| N/A | Clinical Assistant Professor, Arthritis and Clinical Immunology | 50.0 |
Highest
|
$269,260 | $33,105 | $302,365 |
| N/A | Professor, Cardiovascular Biology | 50.0 |
Highest
|
$320,317 | $40,908 | $361,225 |
| N/A | Professor, Arthritis and Clinical Immunology | 50.0 |
Highest
|
$252,606 | $27,462 | $280,068 |
| N/A | Professor, Arthritis and Clinical Immunology | 50.0 |
Highest
|
$309,096 | $53,584 | $362,680 |
| Year | Revenue | Expenses | Assets | Net Income |
|---|---|---|---|---|
| 2025 | No data | No data | No data | No data |
| 2024 | No data | No data | No data | No data |
| 2023 | $114,311,660 | $108,085,497 | $485,930,868 | $6,226,163 |
| 2022 | $107,744,875 | $96,940,173 | $463,812,009 | $10,804,702 |
| 2021 | $126,016,814 | $92,338,587 | $499,810,540 | $33,678,227 |
| 2020 | $95,128,697 | $88,608,525 | $416,096,679 | $6,520,172 |
| 2019 | $96,525,070 | $89,532,385 | $415,080,137 | $6,992,685 |
| 2018 | $91,783,174 | $89,209,656 | $404,739,259 | $2,573,518 |
Compare Oklahoma Medical Research Foundation with other nonprofits in Oklahoma and across the country.